Mauna Kea Technologies SA (EPA:ALMKT)
France
· Delayed Price · Currency is EUR | Market Cap | 15.77M |
| Revenue (ttm) | 8.18M |
| Net Income (ttm) | -10.39M |
| Shares Out | 94.87M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,380,286 |
| Average Volume | 2,430,709 |
| Open | 0.180 |
| Previous Close | 0.176 |
| Day's Range | 0.165 - 0.185 |
| 52-Week Range | 0.061 - 0.194 |
| Beta | 1.28 |
| RSI | 65.97 |
| Earnings Date | Apr 9, 2026 |
About Mauna Kea Technologies
Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate reactions as they occur, classify areas of uncertainty, guide surgical interventions, and help diagnose and treat patients. The company was incorporat... [Read more]
Financial Performance
In 2024, Mauna Kea Technologies's revenue was 8.42 million, a decrease of -23.69% compared to the previous year's 11.03 million. Losses were -10.40 million, 179.2% more than in 2023.
Financial StatementsNews
Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes • news
A major regulatory milestone in the European commercial expansion strategy
Mauna Kea Technologies SA 2025 Q2 - Results - Earnings Call Presentation
Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring • news
Mauna Kea Technologies Announces 2025 Half-Year Results
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p...
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary platform for probe-based and needle-based confocal lase...
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p...
Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery
MELBOURNE, Australia and PARIS , Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Paris-based Mauna Kea Technologies (Euronext Growth: ALMKT, Mauna Kea), ...
Mauna Kea Technologies Reports its Financial Results for the First Half of 2022
Improvement in gross margin driven by a more favorable sales mix and reduction in operating loss. Solid business activity following strategic repositioning and reallocation of resources. Cash position...